TLXTelix Pharmaceuticals
About Telix Pharmaceuticals
Telix Pharmaceuticals (TLX:ASX) is a clinical-stage biopharmaceutical company developing a portfolio of diagnostic and therapeutic radiopharmaceuticals to address significant unmet needs in oncology and rare diseases. Telix's radiopharmaceuticals are designed to target and treat cancer cells or other diseased cells with precision, while minimising damage to healthy tissue. Telix's objectives are to advance its portfolio of radiopharmaceutical products through clinical development and into commercialisation, to become a leading global radiopharmaceutical company, and to improve the lives of patients with cancer and rare diseases.
What is TLX known for?
Snapshot
Public AU
Ownership
2015
Year founded
315
Employees
Melbourne, Australia
Head office
1 of 220
AU Rank
Healthcare
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Melbourne, AU
Produtos e/ou serviços de Telix Pharmaceuticals
- Development of new radiopharmaceutical products: Telix is developing a portfolio of radiopharmaceutical products to address significant unmet needs in oncology and rare diseases.
- Expansion of global clinical trials program: Telix is expanding its global clinical trials program to evaluate the safety and efficacy of its radiopharmaceutical products in patients with cancer and rare diseases.
- Commercialisation of Illuccix in the United States: Telix is commercialising Illuccix, its first product, in the United States for the diagnosis of prostate cancer.
- Diagnostic radiopharmaceuticals: Telix is developing diagnostic radiopharmaceuticals to help clinicians diagnose cancer and other diseases more accurately and efficiently.
- Therapeutic radiopharmaceuticals: Telix is developing therapeutic radiopharmaceuticals to deliver targeted radiation therapy to cancer cells, while minimising damage to healthy tissue.
equipe executiva do Telix Pharmaceuticals
- Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.DCo-Founder, MD, Group CEO & Executive Director
- Mr. Darren Smith B.Bus., FCPA, M.B.A.Group Chief Financial Officer
- Mr. Darren Patti Pharm.D.Group Chief Operating Officer
- Dr. Andreas Kluge M.D., Ph.D.Chief Medical Advisor
- Dr. David N. Cade M.B.A., M.D., MBBSGroup Chief Medical Officer
- Mr. Richard Valeix M.B.A.Chief Executive Officer of Telix Therapeutics
- Dr. Paul SchafferSVP of Research & Development
- Mr. Craig UlrickChief Information Officer
- Ms. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor Relations
- Ms. Lena Moran-Adams L.L.B.Group General Counsel